CS Medica A/S announced a strategic partnership with 180° Drug Store to penetrate Germany and key markets in the Gulf Cooperation Council (GCC). This initiative is a cornerstone of CS MEDICA's pull strategy, drawing on the demand for its innovative treatments in pain management, autoimmune and stress-related disorders. This new partnership with 180° Drug Store underscores its mission to alleviate the pain and discomfort associated with the conditions it aims to treat.

The channel strategy, i.e., has been a catalyst from Italy, where an own-label partner has already placed four orders within six months, to Australia, where the first paid invoice for production of the CANNASEN pain patch demonstrates the effectiveness of new strategy after months of delay in registration. The financial model underpinning this alliance is robust and structured, with a 100% prepayment upon registration approval. Anticipated first-year sales, post-approval, are projected at 440,000 units within Germany and the GCC.

For the GCC, the compliance process is underway to secure necessary local registrations before initiating production. In contrast, Germany is approved for sale under the EU MDR (Medical Device Regulation) but the launch will run parallel with the GCC go-to-market track as the own-label brand is currently planned as a joint production.